Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Toelg R, Fiedler KA, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Book Volume: 35
Pages Range: 2285-2294
Journal Issue: 34
Abstract
Aims Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials.
Involved external institutions
Technische Universität Dresden
Germany (DE)
Segeberger Kliniken
Germany (DE)
Munich Heart Alliance am Institut für Pharmakologie und Toxikologie
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University of Leicester
United Kingdom (GB)
Germany (DE)
Segeberger Kliniken
Germany (DE)
Munich Heart Alliance am Institut für Pharmakologie und Toxikologie
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Icahn School of Medicine at Mount Sinai
United States (USA) (US)
University of Leicester
United Kingdom (GB)
How to cite
APA:
Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P.,... Kastrati, A. (2014). Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 35(34), 2285-2294. https://dx.doi.org/10.1093/eurheartj/ehu182
MLA:
Schulz, Stefanie, et al. "Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction." European Heart Journal 35.34 (2014): 2285-2294.
BibTeX: Download